Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors

Yong Soon Shin1 and Jeong Hoon Kim2*

Abstract

Background: The European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module has been translated into Korean, but to date, its reliability and validity have been evaluated in a pilot study alone. The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire is, overall, a valid instrument to assess the health-related quality of life in Korean cancer patients, although its reliability and validity have not yet been evaluated in patients with brain tumors. This study aimed at evaluating the psychometric properties of these instruments in patients with brain tumors.

Findings: The 2 instruments were used for 307 Korean patients with brain tumors. Multi-trait scaling confirmed the scale structure of the instruments with good item convergent and discriminant validity. The reliability was acceptable for all scales except for cognitive functioning and nausea and vomiting. The instruments could be used to distinguish between clinically distinct groups of patients.

Conclusions: The study findings indicate that the instruments are valid and suitable for the assessment of the health-related quality of life in patients with brain tumors as well as in those with primary brain cancer.

Keywords: Brain tumor, Health-related quality of life, QLQ-BN20, QLQ-C30, Validation, Korea

Background

Despite improvements, many treatments for brain tumors are not curative and these patients have a poor prognosis. In addition, such treatments may be neurotoxic and, thus, negatively affect patient health-related quality of life (HRQOL). Therefore, the use of well-validated instruments when assessing the HRQOL of patients with brain tumors is particularly important. Most HRQOL instruments were developed in English for a predominantly English-speaking population. The European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) has previously been tested in English-speaking patients and was shown to have adequate psychometric properties [1]. The QLQ-BN20 was translated into Korean by the EORTC group [2], and its reliability and validity have been evaluated, although only in a pilot study. The standard Korean version of EORTC Quality of Life Core Questionnaire (QLQ-C30) is, overall, a valid instrument for the assessment of HRQOL in Korean patients with breast, stomach, colon, and rectal cancers [3], although its reliability and validity have not yet been specifically evaluated in patients with brain tumors. Hence, the purpose of the current study was to examine the validity and reliability of the Korean version of the QLQ-BN20 and QLQ-C30 in patients with brain tumors.

Methods

Sample and setting

This study used a prospective, descriptive cross-sectional design in which the convenience sampling was performed at a tertiary-care university hospital in Seoul, Korea. To be included in the study, patients had to be...
aged >18 years, fluent in Korean, and diagnosed with a histologically verified brain tumor. Patients who had not undergone surgery or those with metastatic brain tumors were excluded. The study was approved by the institutional review board of Asan Medical Center. Written informed consent was obtained from all patients or their legally authorized representative.

Instruments
The EORTC QLQ-BN20 is a 20-item questionnaire grouped into 4 domains and 7 single items [1], while the QLQ-C30 comprises a 30-item questionnaire. Raw scores were standardized by linear transformation so that the final scores were in the range of 0–100. Higher scores on the global QOL and functional scales represent a better QOL, whereas high symptom scale scores indicate significant symptoms or greater difficulty.

Statistical analysis
Multi-trait scaling was employed to examine the scale structure of the instruments. Item-scale correlations ≥ 0.40 were considered to validate item convergent. Item-scale discriminant validity was examined by comparing the correlation of each item with its own scale versus that with other scales. We expected a high correlation between items (2 standard errors) with their own scale rather than with other scales. The internal consistency reliability of the instruments was estimated using Cronbach’s alpha coefficient (α). Values of α ≥ 0.70 were considered acceptable for group comparisons.

The known group validities were tested by comparing the score of the Korean version of the QLQ-BN20 and QLQ-C30 between patient groups. First, we hypothesized that patients with a high performance status (Karnofsky performance scale [KPS] score > 70) would report lower levels of symptoms and a better QOL than patients with a low performance status (KPS score ≤ 70). Second, patients with glioma were expected to report a higher level of symptoms than patients with meningioma. Finally, patients who received adjuvant therapy (chemotherapy, radiation therapy, or both) were expected to report a higher level of future uncertainty than patients who underwent surgery alone.

Construct validity was then examined by calculating the correlations between the multi-item scales of the QLQ-BN20 and QLQ-C30. We expected moderate correlations between future uncertainty and emotional functioning, visual disorder and cognitive functioning, motor dysfunction and physical functioning, and communication deficit and social functioning ($r > 0.40$). We used SPSS 20.0 (SPSS Inc., Chicago, IL, USA) for data analysis. Values of $p < 0.05$ were considered statistically significant. Missing data were excluded from the analysis.

Results
Of 350 invited patients, 317 (90.6%) agreed to participate, and a total of 307 (87.7%) useful questionnaires were analysed. The mean age was 47.95 ± 13.64 years (range, 18–81 years). Fifty-seven percent of the patients were women. Most patients were married (72%), and 37.5% had completed college or graduate school. Gliomas (39.7%) constituted the most frequent tumor type. More than half of the patients underwent surgery alone (Table 1).

Scale reliability and scale structures
As shown Table 2, with the exception of the cognitive functioning (0.60) and nausea and vomiting scales (0.64), most of the multi-item scales of the QLQ-C30 and all scales of the QLQ-BN20 met the minimal standard of reliability ($α > 0.70$).

The all-item scale of the QLQ-C30 correlated with its own scale with a value of $r ≥ 0.50$, corrected for overlap, and met the recommended psychometric standards. Item-scale correlations of the QLQ-BN20 indicated that

| Table 1 Socio-demographic and clinical characteristics (N=307) |
|----------------------|----------------------|
| Variable             | Mean (SD, range) or N (%) |
| Age (years)          | 47.95 (13.64, 18–81)   |
| Gender               |                      |
| Female               | 175 (57.0)            |
| Male                 | 132 (43.0)            |
| Education            |                      |
| Middle school or less| 77 (25.1)             |
| High school          | 104 (33.9)            |
| College              | 105 (34.2)            |
| Graduate school      | 10 (3.3)              |
| Nonresponse          | 11 (3.5)              |
| Marital status       |                      |
| Married              | 221 (72.0)            |
| Single               | 53 (17.3)             |
| Widowed/divorced     | 27 (8.8)              |
| Nonresponse          | 6 (1.9)               |
| KPS                  |                      |
| ≤70                  | 35 (11.4)             |
| >70                  | 272 (88.6)            |
| Treatment modality   |                      |
| Surgery only         | 177 (57.7)            |
| Surgery plus CTx or RTx or both | 130 (42.3) |
| Tumor type           |                      |
| Glioma               | 122 (39.7)            |
| Meningioma           | 107 (34.9)            |
| Others               | 78 (25.4)             |

KPS, Karnofsky performance scale; CTx, chemotherapy; RTx, radiation therapy.
each item had a stronger significant correlation with its own scale (range, 0.72–0.92) than with other scales (range, 0.18–0.50).

Clinical validity
As hypothesized, patients with higher KPS scores had significantly better functioning and lower symptom scores on all of the QLQ-C30 and QLQ-BN20 multi-item scales than patients with lower KPS scores ($p < 0.001–0.005$, Table 3). Patients with glioma had significantly lower physical, cognitive, and social functioning scores as well as higher future uncertainty, motor dysfunction, and communication deficits than patients with meningioma ($p < 0.001–0.02$). Patients who underwent surgery plus adjuvant therapy reported lower functioning ($p < 0.001–0.03$) and poor QOL ($p = 0.01$), but higher future uncertainty ($p = 0.02$) and great communication deficits ($p = 0.03$) than those who underwent surgery alone. The 4 scales of the QLQ-BN20 were moderately correlated with some of the QLQ-C30 scales as hypothesized ($r = -0.410 – -0.642$, Table 4).

Discussion
The validity and reliability of the EORTC QLQ-BN20 and QLQ-C30 have been shown in studies across various countries [4,5]. Here we present the results of a study using the Korean version of the QLQ-BN20 and QLQ-C30 in patients with brain tumors.

Table 2 Scale reliability and structures

|                      | Mean (SD)   | Cronbach’s alpha | Number of items | Item-own scale correlation | Item-other scale correlation |
|----------------------|-------------|-------------------|-----------------|----------------------------|-----------------------------|
| **QLQ-C30**          |             |                   |                 |                            |                             |
| **Functional scales**|             |                   |                 |                            |                             |
| Physical functioning | 71.16 (24.94) | .87               | 5               | 0.55–0.90                  | 0.16–0.55                   |
| Role functioning     | 69.74 (31.43) | .89               | 2               | 0.93–0.94                  | 0.25–0.69                   |
| Emotional functioning| 71.51 (23.81) | .87               | 4               | 0.79–0.87                  | 0.27–0.56                   |
| Cognitive functioning| 69.82 (25.80) | .60               | 2               | 0.77–0.87                  | 0.23–0.55                   |
| Social functioning   | 71.73 (30.72) | .85               | 2               | 0.90–0.94                  | 0.28–0.50                   |
| **Global quality of life** | 54.19 (25.18) | .88               | 2               | 0.94–0.94                  | 0.29–0.50                   |
| **Symptom scales/items** |             |                   |                 |                            |                             |
| Fatigue              | 37.42 (23.04) | .77               | 3               | 0.76–0.87                  | 0.27–0.62                   |
| Nausea and vomiting  | 11.67 (17.53) | .64               | 2               | 0.66–0.94                  | 0.19–0.38                   |
| Pain                 | 25.11 (26.93) | .81               | 2               | 0.89–0.91                  | 0.26–0.55                   |
| Dyspnea              | 20.37 (26.22) |                 | 1               | 1.00                       | 0.30–0.51                   |
| Sleep disturbance    | 25.08 (31.61) |                 | 1               | 1.00                       | 0.27–0.44                   |
| Appetite loss        | 16.94 (24.90) |                 | 1               | 1.00                       | 0.21–0.42                   |
| Constipation         | 17.10 (25.78) |                 | 1               | 1.00                       | 0.14–0.25                   |
| Dianhea              | 12.46 (22.57) |                 | 1               | 1.00                       | 0.12–0.20                   |
| Financial difficulty | 31.38 (35.19) |                 | 1               | 1.00                       | 0.24–0.63                   |
| **QLQ-BN20 scales**  |             |                   |                 |                            |                             |
| Future uncertainty   | 34.38 (23.67) | .80               | 4               | 0.72–0.84                  | 0.21–0.47                   |
| Visual disorder      | 27.27 (28.32) | .83               | 3               | 0.73–0.90                  | 0.19–0.36                   |
| Motor dysfunction    | 29.14 (28.92) | .85               | 3               | 0.81–0.85                  | 0.25–0.49                   |
| Communication deficit| 22.41 (27.82) | .90               | 3               | 0.84–0.92                  | 0.18–0.50                   |
| **QLQ-BN20 single items** |             |                   |                 |                            |                             |
| Headache             | 33.44 (31.07) |                 | 1               | 1.00                       | 0.30–0.41                   |
| Seizure              | 9.84 (23.06)  |                 | 1               | 1.00                       | 0.13–0.32                   |
| Drowsiness           | 43.32 (28.03) |                 | 1               | 1.00                       | 0.26–0.42                   |
| Hair loss            | 21.57 (31.01) |                 | 1               | 1.00                       | 0.00–0.26                   |
| Itchy skin           | 16.61 (25.05) |                 | 1               | 1.00                       | 0.16–0.26                   |
| Weakness of legs     | 35.42 (33.27) |                 | 1               | 1.00                       | 0.28–0.73                   |
| Bladder control      | 21.39 (30.88) |                 | 1               | 1.00                       | 0.28–0.39                   |

QLQ-C30 Quality of Life Core Questionnaire, QLQ-BN20 Quality of Life Questionnaire Brain Cancer Module.
The internal consistency reliability coefficients of the QLQ-BN20 were high, although our subjects had various types of brain tumors. These reliability coefficients are higher than those reported in studies of the English [1] and other language versions [4,6]. Our results suggest that the QLQ-BN20 can be used to assess the HRQOL of patients with other brain tumors as well as in those with brain cancer.

Most of the item-subscale correlation coefficients in the QLQ-C30 met the required convergent and discriminant validity standards. This has not always been the case; for example, the structures of the Mexican-Spanish and Greek versions of the QLC-C30 had weaknesses with respect to both their assessment of the cognitive functioning scale and the nausea and vomiting item [7-10]. In this study, we confirmed that the cognitive functioning scale and the nausea and vomiting item were improved as shown in an earlier study of Korean patients with cancer [3].

Most scores of the 2 instruments could clearly distinguish between patient groups according to performance status as shown in earlier studies [4,6,10,11]. The second hypothesis, that the 2 instruments could distinguish patients with glioma from those with meningioma, was partially supported. A Chinese group [12] reported that most scores of the EORTC-C30 were able to distinguish among patients with different brain tumor types. However, they did not compare differences of functioning, QOL and symptoms among specific tumor types (e.g. glioma vs meningioma) using a post-hoc test.

The third hypothesis, that the adjuvant treatment group had greater future uncertainty than the group who underwent surgery alone, was supported. This may have been because the patients who received adjuvant therapy after surgery perceived themselves to have more severe disease than those who underwent surgery alone. Finally, we confirmed that the construction validities of the QLQ-BN20 and QLQ-C30 were acceptable, with correlation coefficients values of $r > 0.40$. These results

| Table 3 Mean scores (standard deviation) of clinically distinct groups                  |
|-----------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Performance status                              | Tumor type            | Treatment modality  |
| KPS≤70                                         | KPS>70               |                      |                      |                      |
| GLQ C30                                        |                      |                      |                      |                      |
| PF                                             | 29.8 (27.4)          | 76.4 (19.0)         | <0.01               | 66.2 (29.0)          | 75.1 (20.0)         | 73.7 (22.8)         | .02*               | 73.8 (22.2)         | 67.6 (27.9)         | .11                |
| RF                                             | 27.3 (31.1)          | 74.9 (27.3)         | <0.01               | 64.5 (35.7)          | 74.5 (24.7)         | 71.5 (31.6)         | .05                | 71.8 (27.8)         | 66.9 (35.7)         | .04                |
| EF                                             | 56.2 (26.6)          | 73.5 (22.7)         | <0.01               | 68.4 (24.8)          | 74.1 (20.6)         | 72.9 (26.0)         | .18                | 71.2 (24.1)         | 71.9 (23.5)         | .89                |
| CF                                             | 42.9 (30.3)          | 73.3 (23.0)         | <0.01               | 64.1 (27.7)          | 73.2 (24.6)         | 74.2 (22.7)         | .008               | 72.3 (25.3)         | 66.4 (26.2)         | .03                |
| SF                                             | 36.3 (32.7)          | 76.2 (27.4)         | <0.01               | 63.6 (33.6)          | 81.0 (26.4)         | 71.9 (29.4)         | <0.01              | 77.2 (28.2)         | 64.2 (32.5)         | <0.01              |
| QOL                                            | 29.4 (22.3)          | 57.3 (23.8)         | <0.01               | 50.8 (26.3)          | 58.1 (23.9)         | 54.1 (24.6)         | .09                | 57.3 (24.7)         | 50.0 (25.4)         | .01                |
| FA                                             | 56.5 (24.2)          | 35.0 (21.7)         | <0.01               | 40.4 (25.6)          | 34.2 (20.4)         | 37.3 (21.9)         | .13                | 36.2 (21.6)         | 39.2 (24.8)         | .24                |
| NV                                             | 21.4 (25.1)          | 104 (15.9)          | .005                | 13.9 (18.7)          | 9.0 (14.4)          | 11.8 (19.2)         | .12                | 10.9 (17.9)         | 12.7 (17.0)         | .05                |
| PA                                             | 51.4 (29.8)          | 21.7 (24.6)         | <0.01               | 26.2 (29.6)          | 23.7 (24.0)         | 25.2 (26.6)         | .79                | 25.8 (26.3)         | 24.2 (27.9)         | .36                |
| QLQ BN20                                       |                      |                      |                      |                      |                      |                      |                    |                    |                    |                    |
| FU                                             | 47.1 (26.6)          | 32.7 (22.8)         | .002                | 38.5 (24.2)          | 28.2 (21.1)         | 36.5 (24.7)         | .003               | 32.0 (23.8)         | 37.5 (23.3)         | .02                |
| MD                                             | 73.7 (29.4)          | 23.4 (23.3)         | <0.01               | 34.2 (32.6)          | 23.4 (23.0)         | 29.2 (28.9)         | .02*               | 26.9 (26.3)         | 32.2 (32.0)         | .33                |
| CD                                             | 47.7 (34.5)          | 19.2 (25.2)         | <0.01               | 30.1 (31.4)          | 16.0 (23.4)         | 19.1 (24.7)         | <0.01              | 19.3 (25.9)         | 26.6 (29.8)         | .03                |

Table 4 Correlations between the Korean versions of the QLQ-C30 and QLQ-BN20

| Table 4 Correlations between the Korean versions of the QLQ-C30 and QLQ-BN20                  |
|-----------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| C30-PF                                        | C30-RF              | C30-EF              | C30-CF              | C30-SF              | C30-QOL             |
| BN20 - FU                                      |                      |                      |                      |                      |                      |
| PF                                             | -475*               | -455*               | -634*               | -486*               | -534*               | -548*               |
| RF                                             | -319*               | -340*               | -367*               | -447*               | -282*               | -348*               |
| EF                                             | -642*               | -617*               | -499*               | -553*               | -532*               | -507*               |
| CF                                             | -379*               | -396*               | -388*               | -511*               | -410*               | -378*               |

* Correlation is significant at the 0.01 level (2-tailed).

KPS Karnofsky performance scale, OP operation, QLQ-C30 Quality of Life Core Questionnaire, PF physical functioning, RF role functionning, EF emotional functioning, CF cognitive functioning, SF social functioning, QOL quality of life; FU future uncertainty, MD motor dysfunction, CD communication deficit.
are similar to those of the previous validation studies of the QLQ-BN20 and QLQ-C30 conducted for patients speaking English [1], Persian [6], and 15 other languages [4].

The present study had some limitations. First, there might have been sampling bias since all participants were recruited from a single hospital and accurate sample size for this study was not calculated. Second, we did not include responsiveness analysis because of the lack of follow-up data. Therefore, these results should be carefully interpreted and implemented.

In conclusion, our findings suggest that the Korean versions of the EORTC QLQ-BN20 and QLQ-C30 are clinically valid and reliable for measuring HRQOL and are suitable for use in both clinical practice and clinical studies, involving Korean patients with brain tumors.

Abbreviations

EORTC QLQ-BN20: European organization for research and treatment of cancer quality of life questionnaire brain cancer module; HRQOL: Health-related quality of life; EORTC QLQ-C30: Quality of life core questionnaire; QOL: Quality of life; KPS: Karnofsky performance scale.

Competing interests

The authors confirm that no research funding or any support was received for this study and declare that they have no financial or other conflicts of interest related to this research and its publication.

Authors’ contributions

SYS and KJH designed the study, KJH collected the data, and both SYS and KJH interpreted the data and revised the manuscript. SYS managed the statistical analysis. Both authors read and approved the final manuscript.

Author details

1Department of Nursing, Changwon National University, 92 Toechonno, Uichang-gu, Changwon, Gyeongnam 641-773, South Korea. 2Department of Neurology Surgery, University of Ulsan College of Medicine, Asan Medical Center, Asanhyeonongwon-gil 86, Songpa-gu, Seoul 138-736, South Korea.

Received: 14 February 2013 Accepted: 6 August 2013

References

1. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E: The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996, 5:139–150.

2. List of translations available by language – validated modules and C30. http://groups.eortc.be/qol/sites/default/files/img/sidebar/ validated_modules_by_june2015.pdf?width=900&height=700&frame=true.

3. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, You CH, West K: Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 2004, 13:863–868.

4. Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, Stupp R, Milmannof RO, Van den Bent MJ, Bottomley A: An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 2010, 46:1033–1040.

5. Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, Slotman BJ, Klein M: Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol 2011, 29:4430–4435.

6. Khosrhevanian A, Yekaninejad MS, Arskani SK, Palpour AH, Mardani A, Aaronson NK: Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran. Health Qual Life Outcomes 2012, 10:54.

7. Carrillo JF, Ortiz-Toledo MA, Salido-Noriega Z, Romero-Ventura NB, Ochoa-Carrillo FJ, Onate-Ocana LF: Validation of the Mexican Spanish version of the EORTC QLQ-H&N35 instrument to measure health-related quality of life in patients with head and neck cancers. Ann Surg Oncol 2012, 20(5):1417–1426.

8. Cerezo O, Onate-Ocana LF, Arrieta-Joffe P, Gonzalez-Lara F, Garcia-Pasquel MJ, Bargallo-Rocha E, Vilarr-Compte D: Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR23 questionnaires to assess health-related quality of life in Mexican women with breast cancer. Eur J Cancer Care (Engl) 2012, 21:684–691.

9. Kontodimopoulos N, Niinouls K, Niakas D: Validity of the Greek EORTC QLQ-C30 and QLQ-BR23 for measuring health-related quality of life in breast cancer patients. Eur J Cancer Care (Engl) 2011, 20:354–361.

10. Onate-Ocana LF, Aicantara-Pilar A, Vilarr-Compte D, Garcia-Hubard G, Rojas-Cartillo E, Alvarez-Aguilar S, Carrillo JF, Blazey JM, Aiello-Crocifoglio V: Validation of the Mexican Spanish version of the EORTC C30 and STO22 questionnaires for the evaluation of health-related quality of life in patients with gastric cancer. Ann Surg Oncol 2009, 16:88–95.

11. Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H, Yoneda S, Noguchi Y, Ogasawara H, Yoshida K: A cross-validation of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 1998, 34:810–815.

12. Cheng JX, Liu BL, Zhang X, Zhang YQ, Lin W, Wang R, Zhang HY, Xie L, Huo JL: The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China. BMC Med Res Methodol 2011, 11:56.

doi:10.1186/1477-7525-11-145
Cite this article as: Shin and Kim: Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors. Health and Quality of Life Outcomes 2013 11:145.